SCHEMBL5339671

SCHEMBL5339671

Nc1ccc(Oc2ccnc(-c3ncon3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
APAF1 O14727 1/20 0.39
ALDH1A1 P00352 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
KDM4E B2RXH2 2/20 0.35
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
POLB P06746 2/20 0.33
RAB9A P51151 1/20 0.33
MAOA P21397 2/20 0.33
F2 P00734 2/20 0.32
F10 P00742 2/20 0.32
PRSS1 P07477 2/20 0.32
PRSS2 P07478 2/20 0.32
PRSS3 P35030 2/20 0.32
ST14 Q9Y5Y6 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28419768 0.82 MEN1 (0.55) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL5423262 0.78 MET (0.42) MEN1KMT2AALDH1A1POLBRAB9A
SCHEMBL24920836 0.75 PPARA (0.35) MEN1KMT2ACYP3A4PIM1PIM2
SCHEMBL1892428 0.73 MEN1 (0.50) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL4935483 0.72 MEN1 (0.48) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL4932938 0.71 MEN1 (0.44) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL1643575 0.70 MEN1 (0.47) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL5425879 0.68 CCNC (0.43) MEN1KMT2AAPAF1KDM4EPOLB
SCHEMBL70247 0.67 RAB9A (0.48) MEN1KMT2AALDH1A1TDP1CYP3A4
SCHEMBL1643681 0.67 MEN1 (0.43) MEN1KMT2AAPAF1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 MEN1 4271/4885KMT2A 3676/4885APAF1 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.